Novo Nordisk A/S resubmitted to the U.S. FDA the new drug application for its fast-acting insulin aspart.
The treatment is intended to control postprandial glucose excursions in patients with type 1 and type 2 diabetes.
The FDA requested additional information from Novo Nordisk regarding the treatment in October 2016. The Denmark-based drugmaker has complied with the FDA's request and expects to receive feedback from the agency in the last quarter of 2017.
Fast-acting insulin aspart received marketing authorization from the European Commission on Jan. 9 and is under regulatory review in Switzerland, Australia, Brazil, South Africa, Argentina and Israel.